USA Insulin Pump Market & Users, CGM (Continuous Glucose Monitoring) Market & Users, Reimbursement Policy (By States), Diabetes (Type1 & 2) Population, Deal Types, Clinical Trials & Forecast
USA insulin pump market is anticipated to cross US$ 5 Billion by end of the year 2022. Insulin Pump has now become a well-known and a favored device for Type1 diabetes patients in the United States. The easiness of using insulin pump is gaining comprehensive recognition in the market as insulin delivery systems.
United States CGM (Continuous Glucose Monitor) Market to be more than US$ 2 Billion in Future
CGM (Continuous Glucose Monitor) is extremely important across all age groups to manage diabetes efficiently. In the United State, the market of CGM has a huge potential in coming years. From the year 2009 to 2016, Continuous Glucose Monitor users have grown to 35 percent. Many private insurers have started reimbursing CGM based on certain criteria in the United States. Many experts think that CGM is the best tool for diabetes management. For those having several diabetes complications, Continuous Glucose Monitor is very much compatible with that.
In USA by States, Reimbursements of Insulin Pumps, CGM, Diabetes Supplies
According to Renub Research report, we have enclosed many State sponsored programmes, which covers insulin pumps under equipment and supplies. The report also provides reimbursement details on the CGM either by the federal health plan or by the State-sponsored health plan. Nearly every state facilitates diabetes supplies to their city but not all state provides insulin pump. For the state-regulated health insurance policies, all the state law diabetes mandates and least coverage required.
Leading companies Medtronic, Insulet Corporation, Animas Corporation & Tandem Diabetes Care Training Model covered in the Report
In this report we have covered, healthcare providers, diabetes educator and certified product trainer etc give inclusive training to new patients. Moreover, via online portal companies also facilitates training to the new pump user to review the training materials. A complete flow chart of training model of all the 4 companies Medtronic, Insulet Corporation, Animas Corporation & Tandem Diabetes Care is covered in this report.
Renub Research latest study “USA Insulin Pump Market & Users, CGM (Continuous Glucose Monitoring) Market & Users, Reimbursement Policy (By States), Diabetes (Type1 & 2) Population, Deal Types, Clinical Trials & Forecast” provides a detailed and comprehensive insight of the Insulin Pump & CGM (Continuous Glucose Monitoring) Market in United States.
SCOPE OF THE REPORT
1. Medtronic
2. Animas Corporation
3. Insulet Corporation
4. Roche
5. Tandem Diabetes Care
KEY QUESTIONS ANSWERED IN THE REPORT?
United States CGM (Continuous Glucose Monitor) Market to be more than US$ 2 Billion in Future
CGM (Continuous Glucose Monitor) is extremely important across all age groups to manage diabetes efficiently. In the United State, the market of CGM has a huge potential in coming years. From the year 2009 to 2016, Continuous Glucose Monitor users have grown to 35 percent. Many private insurers have started reimbursing CGM based on certain criteria in the United States. Many experts think that CGM is the best tool for diabetes management. For those having several diabetes complications, Continuous Glucose Monitor is very much compatible with that.
In USA by States, Reimbursements of Insulin Pumps, CGM, Diabetes Supplies
According to Renub Research report, we have enclosed many State sponsored programmes, which covers insulin pumps under equipment and supplies. The report also provides reimbursement details on the CGM either by the federal health plan or by the State-sponsored health plan. Nearly every state facilitates diabetes supplies to their city but not all state provides insulin pump. For the state-regulated health insurance policies, all the state law diabetes mandates and least coverage required.
Leading companies Medtronic, Insulet Corporation, Animas Corporation & Tandem Diabetes Care Training Model covered in the Report
In this report we have covered, healthcare providers, diabetes educator and certified product trainer etc give inclusive training to new patients. Moreover, via online portal companies also facilitates training to the new pump user to review the training materials. A complete flow chart of training model of all the 4 companies Medtronic, Insulet Corporation, Animas Corporation & Tandem Diabetes Care is covered in this report.
Renub Research latest study “USA Insulin Pump Market & Users, CGM (Continuous Glucose Monitoring) Market & Users, Reimbursement Policy (By States), Diabetes (Type1 & 2) Population, Deal Types, Clinical Trials & Forecast” provides a detailed and comprehensive insight of the Insulin Pump & CGM (Continuous Glucose Monitoring) Market in United States.
SCOPE OF THE REPORT
- Insulin Pump Market & Forecast: In this report, we have segmented Insulin Pump Market into two part US Type 1 Diabetes Market / Juvenile Diabetes Market and US Type 2 Diabetes Market. Market data from the year 2009 to 2016 and Forecast from the year2017 to the year 2022.
- CGM (Continuous Glucose Monitor) Market & Forecast: In this report, the United States CGM market from the year2009 to 2016 and Forecast from the year 2017 to the year 2022.
- Reimbursement Policy of USA States: In this report, we have covered the details on USA States reimbursement policy for Insulin Pumps, CGM (Continuous Glucose Monitor), Diabetes Supplies (Blood Glucose Devices, Test Strips, Lancets, Disposable Needles, Syringe, Ketone Urine Testing Strips, Pen Delivery, Podiatric Appliances, and Oral Agents for controlling blood sugars).
- Reimbursement Policy of USA Insurance Companies: In this report, we have covered the reimbursement policy of top 4 insurance companies i.e. Blue Cross and Blue Shield, Aetna, Cigna and United Healthcare for insulin Pumps and CGM (Continuous Glucose Monitor).
- Training Models: The total 4 companies Medtronic, Insulet Corporation, Animas Corporation & Tandem Diabetes Care Training program were covered in the report. Under this segment companies Training program for its staff includes physicians, Certified Diabetes Educators (including nurse educators, dietitians and exercise physiologists) and support staff with expertise in insulin pump therapy and Training program for patients is being described through flow chart method.
- Differentiation Points of Insulin Pump Products: In this topic, we discussed the Advantages and Disadvantages of the following insulin pumps: Animas Vibe, Medtronic 530G with Enlite, Insulet OmniPod, Tandem t:slim, Roche Accu-Chek Combo.
- Major Deal Types: Main global deals of the insulin pump include Collaboration Deals, Manufacturing Agreement, Licensing Agreement, Exclusive Agreement and Partnership Deals are covered in this report.
- Clinical Trials of Insulin Pumps: In this Report, we have captured details of clinical trials results for companies on Insulin Pumps. The companies like Medtronic, Insulet Corporation, Tandem Diabetes Care, Roche and Animas Corporation.
- Companies Analysis: In this report, we have covered, all the 5 companies from the following points: Overview, Product Details, Insulin Pump Sales Analysis and Latest Development & Trends in their insulin pumps. The five companies were as follows: Medtronic, Insulet Corporation, Roche, Animas Corporation (Acquired by Johnson & Johnson) and Tandem Diabetes Care.
- Growth Drivers for Insulin Pumps: This topic covers the factors which are helping the Insulin Pump and CGM (Continuous Glucose Monitor) industry to grow.
- Challenges for Insulin Pumps: In this segment, it shows the problems being faced by industry of the Insulin Pump and CGM (Continuous Glucose Monitor) industry.
1. Medtronic
2. Animas Corporation
3. Insulet Corporation
4. Roche
5. Tandem Diabetes Care
KEY QUESTIONS ANSWERED IN THE REPORT?
- What is the Insulin Pump Therapy Market in United States & its growth potential in Future?
- What is the Continuous Glucose Monitor Market in United States & its growth potential in Future?
- What is the number of Type 1 and Type 2 Diabetes patients that use insulin pump?
- What is the number of CGM patients in United States and its Forecast?
- What is the preferred brand of insulin pump in United States?
- Is Insulin Pump Therapy Treatment being covered in the Reimbursement policy of United States?
- What are the major deals of insulin pump?
- What are the latest clinical trials of insulin pump?
- What are the key growth drivers and challenges of insulin pump?
1. EXECUTIVE SUMMARY
2. USA – DIABETES POPULATION (2009 – 2022)
2.1 Diabetes Population (2009 - 2022)
2.2 Type 1 Diabetes (Juvenile Diabetes) Population (2009 – 2022)
2.3 Type 2 Diabetes Population (2009 – 2022)
3. UNITED STATES – INSULIN PUMP USER (2009 – 2022)
3.1 United States – Insulin Pump Type 1 User (2009 – 2022)
3.2 United States – Insulin Pump Type 2 User (2009 – 2022)
4. USA – INSULIN PUMP MARKET (2009 – 2022)
4.1 USA – Insulin Pump Type 1 Market (2009 – 2022)
4.2 United States – Insulin Pump Type 2 Market (2009 – 2022)
5. USA – CGM (CONTINUOUS GLUCOSE MONITORING) USER (2009 – 2022)
6. USA – CGM (CONTINUOUS GLUCOSE MONITORING) MARKET & FORECAST
7. DIFFERENTIATION POINTS OF INSULIN PUMP PRODUCTS IN UNITED STATES
7.1 Animas Vibe
7.2 Medtronic 530G with Enlite
7.3 Insulet OmniPod
7.4 Tandem t:slim
7.5 Roche Accu-Chek Combo
8. TRAINING MODEL FOR PATIENTS & HCP – OF MEDTRONIC, ANIMAS, INSULET CORP & TANDEM DIABETES CARE
8.1 Medtronic
8.1.1 Training Guidelines for Insulin Pump Therapy to New Patients
8.1.2 Training Model for HCP (HealthCare Professional)
8.2 Insulet Corporation
8.2.1 Training Structure for New Patients - Insulet Corporation
8.3 Animas Corporation
8.3.1 Training Modules for New Patients
8.3.2 Training Modules for HCP (Health Care Professional)
8.4 Tandem Diabetes Care
9. USA (BY STATES) – DIABETES SUPPLIES, INSULIN PUMP & PUMP SUPPLIES REIMBURSEMENT POLICIES BY STATE-SPONSORED HEALTH PROGRAM
9.1 CALIFORNIA
9.1.1 People Covered by Insurance Mandates
9.1.2 Equipment and Supplies
9.1.3 Services
9.2 DELAWARE
9.2.1 People Covered by Insurance Mandates
9.2.2 Equipment and Supplies
9.2.3 Services
9.3 FLORIDA
9.3.1 People Covered by Insurance Mandates
9.3.2 Equipment and Supplies
9.3.3 Services
9.4 MASSACHUSETTS
9.4.1 People Covered by Insurance Mandates
9.4.2 Equipment and Supplies
9.4.3 Services
9.5 MICHIGAN
9.5.1 People Covered by Insurance Mandates
9.5.2 Equipment and Supplies
9.5.3 Services
9.6 MONTANA
9.6.1 People Covered by Insurance Mandates
9.6.2 Equipment and Supplies
9.6.3 Services
9.7 NEBRASKA
9.7.1 People Covered by Insurance Mandates
9.7.2 Equipment and Supplies
9.7.3 Services
9.8 NEW JERSEY
9.8.1 People Covered by Insurance Mandates
9.8.2 Equipment and Supplies
9.8.3 Services
9.9 NEW YORK
9.9.1 People Covered by Insurance Mandates
9.9.2 Equipment and Supplies
9.9.3 Services
9.10 OKLAHOMA
9.10.1 People Covered by Insurance Mandates
9.10.2 Equipment and Supplies
9.10.3 Services
9.11 RHODE ISLAND
9.11.1 People Covered by Insurance Mandates
9.11.2 Equipment and Supplies
9.11.3 Services
9.12 SOUTH DAKOTA
9.12.1 People Covered by Insurance Mandates
9.12.2 Equipment and Supplies
9.12.3 Services
9.13 TENNESSEE
9.13.1 People Covered by Insurance Mandates
9.13.2 Equipment and Supplies
9.13.3 Services
9.14 TEXAS
9.14.1 People Covered by Insurance Mandates
9.14.2 Equipment and Supplies
9.14.3 Services
9.15 WASHINGTON
9.15.1 People Covered by Insurance Mandates
9.15.2 Equipment and Supplies
9.15.3 Services
10. TOP PRIVATE INSURER - REIMBURSEMENT POLICY OF INSULIN PUMP AND CGM
10.1 Blue Cross and Blue Shield
10.1.1 Insulin Pump Reimbursement
10.1.2 CGM Reimbursement
10.2 Aetna
10.2.1 Insulin Pump Reimbursement
10.2.2 CGM Reimbursement
10.3 Cigna
10.3.1 Insulin Pump Coverage Policy
10.3.2 CGM Reimbursement Policy
10.4 United Healthcare
10.4.1 Insulin Pump Reimbursement Policy
10.4.2 CGM Reimbursement policy
11. BY COMPANY – USA INSULIN PUMP MARKET SHARE
12. USA INSULIN PUMP MARKET – MAJOR DEAL TYPES
12.1 Collaboration Deals
12.2 Manufacturing Agreement
12.3 Licensing Agreement
12.4 Exclusive Agreement
12.5 Partnerships Deals
13. COMPANIES - INSULIN PUMP CLINICAL TRIALS
13.1 Medtronic
13.2 Insulet Corporation
13.3 Tandem Diabetes Care
13.4 Roche
13.5 Animas Corporation
14. UNITED STATES – KEY PLAYER ANALYSIS
14.1 Medtronic
14.1.1 Overview
14.1.2 Insulin Pump – Product Details
14.1.3 Insulin Pump Sales Analysis (2009 – 2022)
14.1.4 Insulin Pump – Latest Development & Trends
14.2 Insulet Corporation
14.2.1 Overview
14.2.2 Insulin Pump – Product Details
14.2.3 Insulin Pump Sales Analysis (2009 – 2022)
14.2.4 Insulin Pump – Latest Development & Trends
14.3 Roche – Insulin Pump Revenue
14.3.1 Overview
14.3.2 Insulin Pump – Product Details
14.3.3 Insulin Pump Sales Analysis (2009 – 2016)
14.3.4 Insulin Pump – Latest Development & Trends
14.4 Animas Corporation (Acquired by Johnson & Johnson)
14.4.1 Overview
14.4.2 Insulin Pump – Product Details
14.4.3 Insulin Pump Sales Analysis (2009 – 2022)
14.4.4 Insulin Pump – Latest Development & Trends
14.5 Tandem Diabetes Care
14.5.1 Overview
14.5.2 Insulin Pump Product Details
14.5.3 Insulin Pump Sales Analysis (2009 – 2022)
14.5.4 Insulin Pump – Latest Development & Trends
15. GROWTH DRIVERS
15.1 Benefits of Insulin Pump over Multiple Daily Injection
15.2 Lifestyle-Compatible Treatment Options and Technological Advancement in Insulin Pump Devices
16. CHALLENGES
16.1 Safety Issues in Insulin Pump Devices
16.2 Difficulties Associated with the Pump
16.2.1 Weight Gain
16.2.2 Diabetic Ketoacidosis
16.2.3 Infection and Infusion Site Reactions
16.3 Adherence
2. USA – DIABETES POPULATION (2009 – 2022)
2.1 Diabetes Population (2009 - 2022)
2.2 Type 1 Diabetes (Juvenile Diabetes) Population (2009 – 2022)
2.3 Type 2 Diabetes Population (2009 – 2022)
3. UNITED STATES – INSULIN PUMP USER (2009 – 2022)
3.1 United States – Insulin Pump Type 1 User (2009 – 2022)
3.2 United States – Insulin Pump Type 2 User (2009 – 2022)
4. USA – INSULIN PUMP MARKET (2009 – 2022)
4.1 USA – Insulin Pump Type 1 Market (2009 – 2022)
4.2 United States – Insulin Pump Type 2 Market (2009 – 2022)
5. USA – CGM (CONTINUOUS GLUCOSE MONITORING) USER (2009 – 2022)
6. USA – CGM (CONTINUOUS GLUCOSE MONITORING) MARKET & FORECAST
7. DIFFERENTIATION POINTS OF INSULIN PUMP PRODUCTS IN UNITED STATES
7.1 Animas Vibe
7.2 Medtronic 530G with Enlite
7.3 Insulet OmniPod
7.4 Tandem t:slim
7.5 Roche Accu-Chek Combo
8. TRAINING MODEL FOR PATIENTS & HCP – OF MEDTRONIC, ANIMAS, INSULET CORP & TANDEM DIABETES CARE
8.1 Medtronic
8.1.1 Training Guidelines for Insulin Pump Therapy to New Patients
8.1.2 Training Model for HCP (HealthCare Professional)
8.2 Insulet Corporation
8.2.1 Training Structure for New Patients - Insulet Corporation
8.3 Animas Corporation
8.3.1 Training Modules for New Patients
8.3.2 Training Modules for HCP (Health Care Professional)
8.4 Tandem Diabetes Care
9. USA (BY STATES) – DIABETES SUPPLIES, INSULIN PUMP & PUMP SUPPLIES REIMBURSEMENT POLICIES BY STATE-SPONSORED HEALTH PROGRAM
9.1 CALIFORNIA
9.1.1 People Covered by Insurance Mandates
9.1.2 Equipment and Supplies
9.1.3 Services
9.2 DELAWARE
9.2.1 People Covered by Insurance Mandates
9.2.2 Equipment and Supplies
9.2.3 Services
9.3 FLORIDA
9.3.1 People Covered by Insurance Mandates
9.3.2 Equipment and Supplies
9.3.3 Services
9.4 MASSACHUSETTS
9.4.1 People Covered by Insurance Mandates
9.4.2 Equipment and Supplies
9.4.3 Services
9.5 MICHIGAN
9.5.1 People Covered by Insurance Mandates
9.5.2 Equipment and Supplies
9.5.3 Services
9.6 MONTANA
9.6.1 People Covered by Insurance Mandates
9.6.2 Equipment and Supplies
9.6.3 Services
9.7 NEBRASKA
9.7.1 People Covered by Insurance Mandates
9.7.2 Equipment and Supplies
9.7.3 Services
9.8 NEW JERSEY
9.8.1 People Covered by Insurance Mandates
9.8.2 Equipment and Supplies
9.8.3 Services
9.9 NEW YORK
9.9.1 People Covered by Insurance Mandates
9.9.2 Equipment and Supplies
9.9.3 Services
9.10 OKLAHOMA
9.10.1 People Covered by Insurance Mandates
9.10.2 Equipment and Supplies
9.10.3 Services
9.11 RHODE ISLAND
9.11.1 People Covered by Insurance Mandates
9.11.2 Equipment and Supplies
9.11.3 Services
9.12 SOUTH DAKOTA
9.12.1 People Covered by Insurance Mandates
9.12.2 Equipment and Supplies
9.12.3 Services
9.13 TENNESSEE
9.13.1 People Covered by Insurance Mandates
9.13.2 Equipment and Supplies
9.13.3 Services
9.14 TEXAS
9.14.1 People Covered by Insurance Mandates
9.14.2 Equipment and Supplies
9.14.3 Services
9.15 WASHINGTON
9.15.1 People Covered by Insurance Mandates
9.15.2 Equipment and Supplies
9.15.3 Services
10. TOP PRIVATE INSURER - REIMBURSEMENT POLICY OF INSULIN PUMP AND CGM
10.1 Blue Cross and Blue Shield
10.1.1 Insulin Pump Reimbursement
10.1.2 CGM Reimbursement
10.2 Aetna
10.2.1 Insulin Pump Reimbursement
10.2.2 CGM Reimbursement
10.3 Cigna
10.3.1 Insulin Pump Coverage Policy
10.3.2 CGM Reimbursement Policy
10.4 United Healthcare
10.4.1 Insulin Pump Reimbursement Policy
10.4.2 CGM Reimbursement policy
11. BY COMPANY – USA INSULIN PUMP MARKET SHARE
12. USA INSULIN PUMP MARKET – MAJOR DEAL TYPES
12.1 Collaboration Deals
12.2 Manufacturing Agreement
12.3 Licensing Agreement
12.4 Exclusive Agreement
12.5 Partnerships Deals
13. COMPANIES - INSULIN PUMP CLINICAL TRIALS
13.1 Medtronic
13.2 Insulet Corporation
13.3 Tandem Diabetes Care
13.4 Roche
13.5 Animas Corporation
14. UNITED STATES – KEY PLAYER ANALYSIS
14.1 Medtronic
14.1.1 Overview
14.1.2 Insulin Pump – Product Details
14.1.3 Insulin Pump Sales Analysis (2009 – 2022)
14.1.4 Insulin Pump – Latest Development & Trends
14.2 Insulet Corporation
14.2.1 Overview
14.2.2 Insulin Pump – Product Details
14.2.3 Insulin Pump Sales Analysis (2009 – 2022)
14.2.4 Insulin Pump – Latest Development & Trends
14.3 Roche – Insulin Pump Revenue
14.3.1 Overview
14.3.2 Insulin Pump – Product Details
14.3.3 Insulin Pump Sales Analysis (2009 – 2016)
14.3.4 Insulin Pump – Latest Development & Trends
14.4 Animas Corporation (Acquired by Johnson & Johnson)
14.4.1 Overview
14.4.2 Insulin Pump – Product Details
14.4.3 Insulin Pump Sales Analysis (2009 – 2022)
14.4.4 Insulin Pump – Latest Development & Trends
14.5 Tandem Diabetes Care
14.5.1 Overview
14.5.2 Insulin Pump Product Details
14.5.3 Insulin Pump Sales Analysis (2009 – 2022)
14.5.4 Insulin Pump – Latest Development & Trends
15. GROWTH DRIVERS
15.1 Benefits of Insulin Pump over Multiple Daily Injection
15.2 Lifestyle-Compatible Treatment Options and Technological Advancement in Insulin Pump Devices
16. CHALLENGES
16.1 Safety Issues in Insulin Pump Devices
16.2 Difficulties Associated with the Pump
16.2.1 Weight Gain
16.2.2 Diabetic Ketoacidosis
16.2.3 Infection and Infusion Site Reactions
16.3 Adherence
LIST OF FIGURES
Figure 2 1: United States – Overall Diabetes Population (Thousand), 2009 - 2016
Figure 2 2: United States – Forecast for Overall Diabetes Population (Thousand), 2017 - 2022
Figure 2 3: United States – Type 1 Diabetes Population (Thousand), 2009 - 2016
Figure 2 4: United States – Forecast for Type 1 Diabetes Population (Thousand), 2017 - 2022
Figure 2 5: United States: Type 2 Diabetes Population (Thousand), 2009 – 2016
Figure 2 6: Forecast for Type 2 Diabetes Population (Thousand), 2017 – 2022
Figure 3 1: United States – Insulin Pump Users (Number), 2009 – 2016
Figure 3 2: United States – Forecast for Insulin Pump Users (Number), 2017 – 2022
Figure 3 3: United States – Type 1 Users of Insulin Pump (Number), 2009 – 2016
Figure 3 4: United States – Forecast for Type 1 Users of Insulin Pump (Number), 2017 – 2022
Figure 3 5: United States – Type 2 Users of Insulin Pump (Number), 2009 – 2016
Figure 3 6: United States – Forecast for Type 2 Users of Insulin Pump (Number), 2017 – 2022
Figure 4 1: United States – Insulin Pump Market (Million US$), 2009 – 2016
Figure 4 2: United States – Forecast for Insulin Pump Market (Million US$), 2017 – 2022
Figure 4 3: United States – Insulin Pump Type 1 Market (Million US$), 2009 – 2016
Figure 4 4: United States – Forecast for Insulin Pump Type 1 Market (Million US$), 2017 – 2022
Figure 4 5: United States – Insulin Pump Type 2 Market (Million US$), 2009 – 2016
Figure 4 6: United States – Forecast for Insulin Pump Type 2 Market (Million US$), 2017 – 2022
Figure 5 1: United States – CGM User (Number), 2009 – 2016
Figure 5 2: United States – Forecast for CGM User (Number), 2017 – 2021
Figure 6 1: United States – CGM Market (Million US$), 2009 – 2016
Figure 6 2: United States – Forecast for CGM Market (Million US$), 2017 – 2022
Figure 11 1: United States – Insulin Pump Preferred Brand (Percent) by Company, 2013
Figure 14 1: United States – Medtronic Insulin Pump Revenue (Million US$), 2009 – 2016
Figure 14 2: United States – Forecast for Medtronic Insulin Pump Revenue (Million US$), 2017 – 2022
Figure 14 3: United States – Insulet Corporation Insulin Pump Revenue (Million US$), 2009 – 2016
Figure 14 4: United States – Forecast for Insulet Corporation Insulin Pump Revenue (Million US$), 2017 – 2022
Figure 14 5: Global – Roche Insulin Pump Revenue (Million US$), 2009 – 2016
Figure 14 6: Global – Animas Corporation Insulin Pump Revenue (Million US$), 2009 – 2016
Figure 14 7: Global – Forecast for Animas Corporation Insulin Pump Revenue (Million US$), 2017 – 2022
Figure 14 8: Global – Tandem Insulin Pump Revenue (Million US$), 2012 – 2016
Figure 14 9: Global – Forecast for Tandem Insulin Pump Revenue (Million US$), 2017 – 2022
Figure 2 1: United States – Overall Diabetes Population (Thousand), 2009 - 2016
Figure 2 2: United States – Forecast for Overall Diabetes Population (Thousand), 2017 - 2022
Figure 2 3: United States – Type 1 Diabetes Population (Thousand), 2009 - 2016
Figure 2 4: United States – Forecast for Type 1 Diabetes Population (Thousand), 2017 - 2022
Figure 2 5: United States: Type 2 Diabetes Population (Thousand), 2009 – 2016
Figure 2 6: Forecast for Type 2 Diabetes Population (Thousand), 2017 – 2022
Figure 3 1: United States – Insulin Pump Users (Number), 2009 – 2016
Figure 3 2: United States – Forecast for Insulin Pump Users (Number), 2017 – 2022
Figure 3 3: United States – Type 1 Users of Insulin Pump (Number), 2009 – 2016
Figure 3 4: United States – Forecast for Type 1 Users of Insulin Pump (Number), 2017 – 2022
Figure 3 5: United States – Type 2 Users of Insulin Pump (Number), 2009 – 2016
Figure 3 6: United States – Forecast for Type 2 Users of Insulin Pump (Number), 2017 – 2022
Figure 4 1: United States – Insulin Pump Market (Million US$), 2009 – 2016
Figure 4 2: United States – Forecast for Insulin Pump Market (Million US$), 2017 – 2022
Figure 4 3: United States – Insulin Pump Type 1 Market (Million US$), 2009 – 2016
Figure 4 4: United States – Forecast for Insulin Pump Type 1 Market (Million US$), 2017 – 2022
Figure 4 5: United States – Insulin Pump Type 2 Market (Million US$), 2009 – 2016
Figure 4 6: United States – Forecast for Insulin Pump Type 2 Market (Million US$), 2017 – 2022
Figure 5 1: United States – CGM User (Number), 2009 – 2016
Figure 5 2: United States – Forecast for CGM User (Number), 2017 – 2021
Figure 6 1: United States – CGM Market (Million US$), 2009 – 2016
Figure 6 2: United States – Forecast for CGM Market (Million US$), 2017 – 2022
Figure 11 1: United States – Insulin Pump Preferred Brand (Percent) by Company, 2013
Figure 14 1: United States – Medtronic Insulin Pump Revenue (Million US$), 2009 – 2016
Figure 14 2: United States – Forecast for Medtronic Insulin Pump Revenue (Million US$), 2017 – 2022
Figure 14 3: United States – Insulet Corporation Insulin Pump Revenue (Million US$), 2009 – 2016
Figure 14 4: United States – Forecast for Insulet Corporation Insulin Pump Revenue (Million US$), 2017 – 2022
Figure 14 5: Global – Roche Insulin Pump Revenue (Million US$), 2009 – 2016
Figure 14 6: Global – Animas Corporation Insulin Pump Revenue (Million US$), 2009 – 2016
Figure 14 7: Global – Forecast for Animas Corporation Insulin Pump Revenue (Million US$), 2017 – 2022
Figure 14 8: Global – Tandem Insulin Pump Revenue (Million US$), 2012 – 2016
Figure 14 9: Global – Forecast for Tandem Insulin Pump Revenue (Million US$), 2017 – 2022
LIST OF TABLES
Table 7 1: United States – Animas Vibe Differentiation Features
Table 7 2: United States – Medtronic 530G with Enlite Differentiation Features
Table 7 3: United States – Insulet OmniPod Differentiation Features
Table 7 4: United States – Tandem t:slim Differentiation Features
Table 7 5: United States – Roche Accu-Chek Combo Differentiation Features
Table 10 1: Blue Cross and Blue Shield - Comparison of Benefits between Standard Option and Basic Option
Table 10 2: Blue Cross and Blue Shield – Insulin Pump Coverage
Table 14 1: Medtronic – Latest Insulin Pump Products
Table 14 2: Insulet Corporation – Latest Products
Table 14 3: Roche Insulin Pump – Latest Products
Table 14 4: Animas Corporation Insulin Pump – Latest Products
Table 14 5: Tandem Insulin Pump – Latest Products
Table 7 1: United States – Animas Vibe Differentiation Features
Table 7 2: United States – Medtronic 530G with Enlite Differentiation Features
Table 7 3: United States – Insulet OmniPod Differentiation Features
Table 7 4: United States – Tandem t:slim Differentiation Features
Table 7 5: United States – Roche Accu-Chek Combo Differentiation Features
Table 10 1: Blue Cross and Blue Shield - Comparison of Benefits between Standard Option and Basic Option
Table 10 2: Blue Cross and Blue Shield – Insulin Pump Coverage
Table 14 1: Medtronic – Latest Insulin Pump Products
Table 14 2: Insulet Corporation – Latest Products
Table 14 3: Roche Insulin Pump – Latest Products
Table 14 4: Animas Corporation Insulin Pump – Latest Products
Table 14 5: Tandem Insulin Pump – Latest Products
